Conference Proceedings

Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.

Andrew J Armstrong, Russell Zelig Szmulewitz, Daniel Peter Petrylak, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Y Alekseev, Taro Iguchi, Neal D Shore, Brad Rosbrook, Jennifer Sugg, Benoit Baron, Lucy F Chen, Arnulf Stenzl

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019

Abstract

687 Background: ENZA, a potent androgen receptor inhibitor, has demonstrated benefit in men with metastatic and nonmetastatic castration-resistant prostate cancer (CRPC). Efficacy of ENZA with ADT in men with mHSPC is unknown. Methods: ARCHES is a multinational, double-blind, phase 3 study (NCT02677896). Patients (pts) with mHSPC were randomized 1:1 to ENZA (160 mg/day) + ADT or PBO + ADT, stratified by disease volume (CHAARTED criteria) and prior docetaxel therapy. Primary endpoint was radiographic progression-free survival (rPFS) assessed centrally or death within 24 weeks of treatment discontinuation. Secondary endpoints included time to prostate-specific antigen (PSA) progression, PSA a..

View full abstract

Grants

Funding Acknowledgements

Medical writing and editing assistance was provided by Stephanie Rippon, MBio, and Lauren Smith from Complete HealthVizion, funded by the study sponsors. This study was funded by Astellas Pharma Inc. and Medivation LLC, a Pfizer Company, the co-developers of enzalutamide. Clinical trial information: NCT02677896.